menu
    • menu
    [{"orgOrder":0,"company":"SonALAsense","sponsor":"Insightec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SonALAsense \/ SonALAsense","highestDevelopmentStatusID":"4","companyTruncated":"SonALAsense \/ SonALAsense"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SonALAsense \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Undisclosed"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SONALA-001","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SonALAsense \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SonALAsense \/ Undisclosed"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SONALA-001","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SonALAsense \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Undisclosed"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Nader Sanai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SONALA-001","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SonALAsense \/ Nader Sanai","highestDevelopmentStatusID":"6","companyTruncated":"SonALAsense \/ Nader Sanai"}]

    Find Clinical Drug Pipeline Developments & Deals by SonALAsense

    Menu

    SonALAsense

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurr...

                            Details : SONALA-001 (aminolevulinic acid) is a porphyrin precursor and optical imaging agent. The mechanism of action of aminolevulinic acid is as a fluorescence contrast activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 08, 2023

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

                            Details : SONALA-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2022

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

                            Details : SONALA-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2021

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Insightec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SonALAsense Pioneers Sonodynamic Therapy Enters Into a Collaboration and License Agreement With Insightec

                            Details : The collaboration aims at conducting a first-in-human clinical trial in rGBM using SonALAsense's innovative Phase 0 approach to rapidly assess safety, and biological and clinical efficacy of aminolevulinic acid (ALA SDT).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 14, 2020

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Insightec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SonALAsense

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Nader Sanai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma

                            Details : SONALA-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2020

                            Lead Product(s) : SONALA-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Nader Sanai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth